[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jumeirah American Clinic\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":82},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100562618","regenerative-injection-of-stem-cells-or-stem-cell-derived-exosomes-for-erectile-dysfunction-rise-100562618",false,"NCT06605508","Regenerative Injection of Stem Cells or Stem Cell-derived Exosomes for Erectile Dysfunction (RISE)","Prospective Observational Study on Intracavernosal Injection of Autologous Adipose Tissue-Derived Stem Cells (ADSC) or Stem Cell-derived Exosomes for the Treatment of Erectile Dysfunction","RISE","Inclusion Criteria:\n\n* Age: Adult males aged 30 to 75 years.\n* Diagnosis: Confirmed diagnosis of erectile dysfunction (ED) of mild to moderate severity, as defined by an International Index of Erectile Function (IIEF) score.\n* Treatment Response: Failure or suboptimal response to conventional ED treatments, such as PDE-5 inhibitors.\n* General Health: Overall good health without contraindications to stem cell therapy.\n* Informed Consent: Ability and willingness to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Severe Cardiovascular Disease: Presence of severe cardiovascular conditions, including uncontrolled hypertension or significant heart disease.\n* Active Infections: Ongoing infections that could interfere with treatment or pose a risk to the participant.\n* Malignancies: History of or current cancer, including malignancies that could affect safety or treatment outcomes.\n* Contraindications to Stem Cell Therapy: Any medical conditions or treatments that contraindicate the use of stem cell therapy.\n* Uncontrolled Diabetes: Poorly controlled diabetes or other metabolic disorders that could impact treatment efficacy or safety.\n* Psychiatric or Cognitive Impairments: Significant psychiatric or cognitive disorders that may affect the participant\\'s ability to comply with study protocols or provide informed consent.\n* Recent Surgery or Trauma: Recent major surgeries or physical trauma that could impact the study or interfere with the intervention.\n* Participation in Other Studies: Participation in other clinical trials or studies that may affect the outcomes or safety of this study.","MALE","30 Years","75 Years",{"count":21,"type":22},30,"ESTIMATED","OBSERVATIONAL","The goal of this prospective observational study is to evaluate whether injections of stem cells derived from the patient's own fat tissue (adipose tissue) can improve erectile function in men aged 30 to 75 who have erectile dysfunction (ED) and have not responded well to standard treatments like PDE-5 inhibitors (e.g., Viagra).\n\nThe main questions the study aims to answer are:\n\nWill the stem cell injections improve erectile function, as measured by the International Index of Erectile Function (IIEF) score? Are there any changes in blood flow to the penis, which will be measured using a Doppler ultrasound?\n\nParticipants will:\n\nReceive injections of their own stem cells (obtained from a biopsy of fat) directly into the penis.\n\nUndergo assessments to check erectile function before and after treatment. Have follow-up visits at 3, 6, 9, and 12 months to monitor long-term effects. The study will also look for any possible side effects or complications and evaluate biological markers in the penis that may indicate the effectiveness of the treatment.\n\nParticipants will be recruited from clinic where they are already receiving care for ED. To take part, they must be in good overall health, with no severe heart disease, uncontrolled diabetes, cancer, or other conditions that could make stem cell therapy unsafe for them.",[26,27,28],"Erectile Dysfunction","Erectile Dysfunction Associated With Type 2 Diabetes Mellitus","Erectile Dysfunction Following Radical Prostatectomy",[30,31,32,33,34],"stem cell therapy","Erectile dysfunction (ED)","Autologous adipose tissue-derived stem cells (ADSC)","Regenerative medicine for ED","Exosomes","RECRUITING","2025-08-25",{"date":38,"type":39},"2025-08-26","ACTUAL",{"date":41,"type":39},"2025-01-10",{"date":43,"type":22},"2029-12-31",{"name":45,"class":46},"Jumeirah American Clinic","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":61,"studyType":23,"phases":4,"briefSummary":62,"conditions":63,"keywords":70,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":79,"leadSponsor":81,"locationsCount":47},"100580747","fertility-enhancement-through-regenerative-treatment-in-ovaries-and-testes-100580747","NCT06841328","Fertility Enhancement Through Regenerative Treatment in Ovaries and Testes","Fertility Enhancement Through Regenerative Treatment in Ovaries and Testes: (FERTILE): Prospective Observational Study Evaluating Safety and Efficacy","FERTILE","Male patients:\n\n* Male patients aged 20 to 50 years.\n* Diagnosed with testicular failure (low testosterone) or hypogonadism (impaired gonadal function), or azoospermia (no sperm in ejaculate)\n* Suboptimal response to conventional treatments, such as testosterone replacement therapy (TRT) or fertility-enhancing medications (Clomiphene citrate or anastrozole).\n* General good health without significant contraindications to stem cell or stem cell-derived exosome therapy.\n* Willing and able to provide informed consent and comply with the study protocol.\n* Patients who have been evaluated for testicular failure and are seeking further treatment.\n\nFemale patients:\n\n* Female patients aged 20 to 50 years.\n* Diagnosed with premature ovarian failure (POF) or ovarian insufficiency, confirmed through clinical, hormonal, and imaging assessments.\n* Failure or suboptimal response to conventional treatments, such as hormone therapy.\n* General good health without significant contraindications to stem cell or stem cell-derived exosome therapy.\n* Willing and able to provide informed consent and comply with the study protocol.\n* Patients who have been evaluated for ovarian failure are seeking further treatment.\n\nExclusion criteria\n\n* Severe comorbid conditions, such as advanced cardiovascular disease, renal failure, or uncontrolled diabetes.\n* Active malignancies or history of cancer within the past 5 years.\n* Active infections or systemic inflammatory conditions.\n* History of testicular surgery or trauma that could interfere with the study outcomes.\n* Use of anticoagulants or medications that may contraindicate stem cell or stem cell-derived exosome therapy.\n* Participation in another investigational drug or treatment study within the past 6 months.\n* Contraindications to stem cell or stem cell-derived exosome therapy, such as immune deficiencies or allergies to any treatment components.\n* Severe neurological disorders or cognitive impairment may limit the ability to provide informed consent or follow study instructions.\n* Any condition that, in the investigator's opinion, could interfere with the study or pose an undue risk to the patient.\n* Women with a primary diagnosis of psychogenic ovarian dysfunction or infertility.\n* History of ovarian surgery or trauma that could interfere with the study outcomes.","ALL","20 Years","50 Years",{"count":60,"type":22},60,"12 Months","This study investigates the safety and efficacy of stem cell or stem cell-derived exosome therapy for gonadal failure, including testicular failure, hypogonadism, ovarian insufficiency, and premature ovarian failure (POF). Conducted at First IVF Clinic, Dubai, it will include 60 participants (30 males, 30 females) aged 20-50 years who have not responded to conventional treatments such as HRT, TRT, or ART.\n\nParticipants will receive intra-gonadal (testicular or ovarian) injections of stem cells or exosomes, with follow-ups at 3, 6, 9, and 12 months to monitor hormonal changes, gonadal function, and potential adverse effects. The study aims to determine whether regenerative therapy can restore hormone production, enhance reproductive function, and regenerate gonadal tissue, providing a novel, culturally appropriate fertility treatment in the UAE, where donor sperm and eggs are not permitted.\n\nBy bridging the gap between preclinical research and clinical application, this study could offer new hope to individuals with gonadal failure, advancing the field of regenerative reproductive medicine.",[64,65,66,67,68,69],"Gonadal Dysfunction","Gonadal Failure","Azoospermia","Testosterone Deficiency","Stem Cells","Hypogonadism, Male",[71,72,73,74,34],"Premature Ovarian Failure","Testicular Failure","low testosterone","Stem cell therapy","2025-04-08",{"date":77,"type":39},"2025-04-10",{"date":75,"type":39},{"date":80,"type":22},"2028-04-30",{"name":45,"class":46},""]